The main objective of this clinical trial is to investigate hepatic fat as the primary endpoint along with body fat, and weight changes after initiation of a basal insulin therapy together with data acquisition that is today's standard in studies investigating obesity and eating patterns with insulin detemir and insulin glargine.

Inclusion Criteria:

• Age > 18 years and < 80 years
• Gender: female, male
• Type 2 diabetes
• BMI: 20.0 - 38.0
• Anti-GAD antibody negative
• Fasting blood glucose > 126 mg/dl
• HbA1c 7.0 - 11.0%
• Need for insulin therapy

Exclusion Criteria:

• Previous therapy with insulin within the last 3 months prior to inclusion into the study
• Previous therapy with glitazones within the last 6 months prior to inclusion into the study
• Change in therapy with lipid-lowering or anti-hypertensive agent within one month prior to inclusion into the study (a stable lipid-lowering or anti-hypertensive therapy is allowed)
• Concomitant participation in other clinical trials
• Type 1 diabetes
• Cardiac and macrovascular disease
• Malignancy including leukaemia and lymphoma within the last 5 years
• Liver disease: cirrhosis or chronic active hepatitis, except fat liver
• Significant renal dysfunction
• other Endocrine disease
• significant laboratory abnormalities
• History of active substance abuse (including an average alcohol consume of > 40g/day and drugs) within the past 2 years
• Female patients: Pregnancy or childbearing potential without adequate contraception (for male patients contraception is not considered as medically important)
• Present therapy with systemic steroids
• Presence of psychiatric disorder or intake of anti-depressive or anti-psychotic agents with the exception of benzodiazepines and SSRIs/SNRI´s
• Use of anti-obesity drugs 3 months prior or during the trial
• Potentially unreliable subjects, probably non compliant subjects, and those judged by the investigator to be unsuitable for the study
• Contraindications for MRI scanning such as persons with cardiac pacemaker and implants out of metal or claustrophobia
• Known hypersensitivity to insulin detemir, insulin glargine or to any of the other components